117 related articles for article (PubMed ID: 33851387)
1. Role of Membrane Lipid Rafts in MRP4 (ABCC4) Dependent Regulation of the cAMP Pathway in Blood Platelets.
Belleville-Rolland T; Leuci A; Mansour A; Decouture B; Martin F; Poirault-Chassac S; Rouaud M; Guerineau H; Dizier B; Pidard D; Gaussem P; Bachelot-Loza C
Thromb Haemost; 2021 Dec; 121(12):1628-1636. PubMed ID: 33851387
[TBL] [Abstract][Full Text] [Related]
2. Reduction of cAMP and cGMP inhibitory effects in human platelets by MRP4-mediated transport.
Borgognone A; Pulcinelli FM
Thromb Haemost; 2012 Nov; 108(5):955-62. PubMed ID: 23014861
[TBL] [Abstract][Full Text] [Related]
3. Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice.
Decouture B; Dreano E; Belleville-Rolland T; Kuci O; Dizier B; Bazaa A; Coqueran B; Lompre AM; Denis CV; Hulot JS; Bachelot-Loza C; Gaussem P
Blood; 2015 Oct; 126(15):1823-30. PubMed ID: 26316625
[TBL] [Abstract][Full Text] [Related]
4. Compartmentalisation of cAMP-dependent signalling in blood platelets: The role of lipid rafts and actin polymerisation.
Raslan Z; Naseem KM
Platelets; 2015; 26(4):349-57. PubMed ID: 24832788
[TBL] [Abstract][Full Text] [Related]
5. Developmental Differences in Platelet Inhibition Response to Prostaglandin E1.
Palma-Barqueros V; Torregrosa JM; Caparrós-Pérez E; Mota-Pérez N; Bohdan N; Llanos MDC; Begonja AJ; Sola-Visner M; Vicente V; Teruel-Montoya R; Rivera J; Ferrer-Marín F
Neonatology; 2020; 117(1):15-23. PubMed ID: 31786577
[TBL] [Abstract][Full Text] [Related]
6. MRP4 (ABCC4) as a potential pharmacologic target for cardiovascular disease.
Belleville-Rolland T; Sassi Y; Decouture B; Dreano E; Hulot JS; Gaussem P; Bachelot-Loza C
Pharmacol Res; 2016 May; 107():381-389. PubMed ID: 27063943
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Fisch A; Michael-Hepp J; Meyer J; Darius H
Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
[TBL] [Abstract][Full Text] [Related]
8. Lipid rafts are required in Galpha(i) signaling downstream of the P2Y12 receptor during ADP-mediated platelet activation.
Quinton TM; Kim S; Jin J; Kunapuli SP
J Thromb Haemost; 2005 May; 3(5):1036-41. PubMed ID: 15869601
[TBL] [Abstract][Full Text] [Related]
9. RETRACTED: The glycoprotein Ib-IX-V complex mediates localization of factor XI to lipid rafts on the platelet membrane.
Baglia FA; Shrimpton CN; López JA; Walsh PN
J Biol Chem; 2003 Jun; 278(24):21744-50. PubMed ID: 12517745
[TBL] [Abstract][Full Text] [Related]
10. Impact of Multidrug Resistance Protein-4 Inhibitors on Modulating Platelet Function and High on-Aspirin Treatment Platelet Reactivity.
Alemanno L; Massimi I; Klaus V; Guarino ML; Maltese T; Frati L; Angiolillo DJ; Pulcinelli FM
Thromb Haemost; 2018 Mar; 118(3):490-501. PubMed ID: 29448294
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
12. Effects of activation of protein kinase C on the agonist-induced stimulation and inhibition of cyclic AMP formation in intact human platelets.
Williams KA; Murphy W; Haslam RJ
Biochem J; 1987 May; 243(3):667-78. PubMed ID: 2444206
[TBL] [Abstract][Full Text] [Related]
13. Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response.
Lin ZP; Zhu YL; Johnson DR; Rice KP; Nottoli T; Hains BC; McGrath J; Waxman SG; Sartorelli AC
Mol Pharmacol; 2008 Jan; 73(1):243-51. PubMed ID: 17959714
[TBL] [Abstract][Full Text] [Related]
14. Release of Platelet-Derived Sphingosine-1-Phosphate Involves Multidrug Resistance Protein 4 (MRP4/ABCC4) and Is Inhibited by Statins.
Vogt K; Mahajan-Thakur S; Wolf R; Bröderdorf S; Vogel C; Böhm A; Ritter CA; Gräler M; Oswald S; Greinacher A; Kroemer HK; Jedlitschky G; Rauch BH
Thromb Haemost; 2018 Jan; 118(1):132-142. PubMed ID: 29304533
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide inhibition of adenylyl cyclase type 6 activity is dependent upon lipid rafts and caveolin signaling complexes.
Ostrom RS; Bundey RA; Insel PA
J Biol Chem; 2004 May; 279(19):19846-53. PubMed ID: 15007069
[TBL] [Abstract][Full Text] [Related]
16. Targeting of type I protein kinase A to lipid rafts is required for platelet inhibition by the 3',5'-cyclic adenosine monophosphate-signaling pathway.
Raslan Z; Magwenzi S; Aburima A; Taskén K; Naseem KM
J Thromb Haemost; 2015 Sep; 13(9):1721-34. PubMed ID: 26176741
[TBL] [Abstract][Full Text] [Related]
17. Effects of cholesterol depletion on compartmentalized cAMP responses in adult cardiac myocytes.
Agarwal SR; MacDougall DA; Tyser R; Pugh SD; Calaghan SC; Harvey RD
J Mol Cell Cardiol; 2011 Mar; 50(3):500-9. PubMed ID: 21115018
[TBL] [Abstract][Full Text] [Related]
18. Involvement of lipid rafts in multiple signal transductions mediated by two isoforms of thromboxane A₂ receptor: dependency on receptor isoforms and downstream signaling types.
Goto S; Saito M; Obara Y; Moriya T; Nakahata N
Eur J Pharmacol; 2012 Oct; 693(1-3):15-24. PubMed ID: 22963705
[TBL] [Abstract][Full Text] [Related]
19. Specific inhibition of the transporter MRP4/ABCC4 affects multiple signaling pathways and thrombus formation in human platelets.
Wolf R; Grammbauer S; Palankar R; Tolksdorf C; Moritz E; Böhm A; Hasan M; Hafkemeyer A; Greinacher A; Tzvetkov MV; Rauch BH; Jedlitschky G
Haematologica; 2022 Sep; 107(9):2206-2217. PubMed ID: 35295075
[TBL] [Abstract][Full Text] [Related]
20. Platelet membrane lipid rafts protein composition varies following GPVI and CLEC-2 receptors activation.
Izquierdo I; Barrachina MN; Hermida-Nogueira L; Casas V; Eble JA; Carrascal M; Abián J; García Á
J Proteomics; 2019 Mar; 195():88-97. PubMed ID: 30677554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
